Company intelligence / Profile preview

PolarityBio

Salt Lake City, Utah, USApolaritybio.com ↗

Ownership: Private
Development stage: Phase 3

Overview

PolarityBio is a clinical-stage biotechnology company developing regenerative tissue products. Its lead asset, SkinTE®, is in a pivotal Phase III trial for Wagner 1 diabetic foot ulcers. The company has received FDA Breakthrough Therapy Designation for SkinTE based on positive Phase II data and is targeting a Biologics License Application after completion of two pivotal studies. Interim enrollment milestones have been met, with an interim analysis expected at the end of Q1 2025. No commercial products yet; investigational use only.

Therapeutic areas: EndocrinologyDermatology
Modalities: Multicomponent biologicsRegenerative tissue product
Industry: Biotech

Drug pipeline

1 asset

SkinTE

Partnerships

Avenue Capital Group/Avenue Venture Opportunities Fund (financing partner)

Beyond the preview

Go deeper on PolarityBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PolarityBio.

Explore the full profile